Physician profile
James D Evans
NPI 1467530675
$832.90
in general payments reported to CMS, 2019-2025
13 companies · $315 in 2025
The $315 reported for 2025 was more than what 87% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $134 · 2021: $152 · 2022: $177 · 2023: $31.43 · 2024: $23.71 · 2025: $315.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $369.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Pharmaceuticals Incorporated | $241.02 | 2022-2025 | Exparel |
| Abiomed | $119.75 | 2025 | |
| Avanos Medical | $116.57 | 2020 | |
| Medtronic, INC. | $101.33 | 2021-2025 | Corevalve Evolut R |
| Abbott Laboratories | $52.48 | 2021 | |
| Ethicon US, LLC | $31.43 | 2023 | Surgiflo Hemostatic Matrix, Echelon Flex |
| Heron Therapeutics, INC. | $30.32 | 2025 | Aponvie |
| Biogen, INC. | $28.66 | 2025 | Vumerity, Tysabri |
| Acacia Pharma INC | $26.99 | 2021 | |
| Becton, Dickinson and Company | $25.76 | 2025 | Hemosphere |
| Merck Sharp & Dohme LLC | $23.71 | 2024 | Bridion |
| Abbvie INC. | $17.77 | 2020 | |
| Octapharma USA, INC. | $17.11 | 2025 | Fibryga |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Evans listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.